{Reference Type}: Journal Article
{Title}: High dose statin treatment reduces circulating Dickkopf-1 following acute myocardial infarction.
{Author}: Ueland T;Butt N;Lekva T;Ørn S;Manhenke C;Aukrust P;Larsen AI;
{Journal}: Int J Cardiol
{Volume}: 406
{Issue}: 0
{Year}: 2024 Jul 1
{Factor}: 4.039
{DOI}: 10.1016/j.ijcard.2024.132035
{Abstract}: <B>BACKGROUND: </B>Secreted glycoproteins of the Dickkopf (DKK) family modify Wnt signaling and may influence plaque destabilization but their modulation by statins in MI patients is not known.<BR><B>METHODS: </B>We measured plasma DKK-1 and DKK-3 in patients with acute ST-segment elevation MI (STEMI) before percutaneous coronary intervention (PCI) and after 2 and 7 days and 2 months in patients receiving short-term high-dose (40 mg rosuvastatin, given before PCI; n = 25) and moderate dose (20 mg simvastatin, given the day after PCI; n = 34). In vitro modulation of DKK-1 in human umbilical vein endothelial cells (HUVECs) by statins were assessed.<BR><B>RESULTS: </B>(i) Patients receiving high dose rosuvastatin had a marked decline in DKK-1 at day 2 which was maintained throughout the study period. However, a more prevalent use of β-blockers in the simvastatin group, that could have contributed to higher DKK-1 levels in these patients. (ii) There was a strong correlation between baseline DKK-1 levels and change in DKK-1 from baseline to day 2 in patients receiving high dose rosuvastatin treatment. (iii) DKK-3 increased at day 2 but returned to baseline levels at 2 months in both treatment groups. (iv) Statin treatment dose-dependently decreased DKK-1 mRNA and protein levels in HUVEC.<BR><B>CONCLUSIONS: </B>Our findings suggest that high dose statin treatment with 40 mg rosuvastatin could persistently down-regulate DKK-1 levels, even at 2 months after the initial event in STEMI patients.